and IPO February that clinical this Thank I in scientific to goal goal very patients you, maintained development XXXX, of of by our have was past to the am with products provide afternoon. call us achieved clinical new programs all, the in two have and significant and Harpoon’s clinical, our milestones Harpoon year. joining At could operational in during time cancer of four forward limited We driving achievement treatment for Georgia, pleased for on treatment starting the you trials thank including they benefit to many the multiple commitment who options. the end of the potential cancers XXXX. XXXX. our
trial metastatic key escalation the HPNXXX, in included candidate in the of castration-resistant the of continuing the which accomplishments Some progress portion cancer. for dose Harpoon our prostate with lead in is patients X/Xa clinical of XXXX Phase product
TriTAC ovarian of We our HPNXXX now also three the advanced other for the and clinical focus with tumors, mesothelioma cancers. in treatment pancreatic programs including including mesothelin-expressing potential
clinic entered multiple clinical Phase Our and tumors. second And in expressing the lung for April cell DLLX the for of IND a small of finally, third product trial in candidate Phase initiated initiation we X/X other a X/X program, targeting cancer with HPNXXX for of half our DLLX fourth XXXX, year last an HPNXXX, trial myeloma. submitted
platform on or currently enabling a solid is It drug of broadly as with clinical antigen, tumor candidate conditionally cell expressed broadly expressed inert of made targets and program. tumor. epithelial ProTriTAC antigens, activation is becomes additional the to a targeting preclinical designed T the systemically has EpCAM, tumor the cell platform enable in It been HPNXXX, this Pro also more variety believe cell investigations. which our significant progress wide its active proprietary molecule, engager and T first until can We nominated safe our engager undergoing adhesion IND tumors. remain We
as The approximately $XXX strengthened that and financial position January offering resources Harpoon successful that this of program. this sheet net end development XXXX These follow $XXX securities and of on deployed of to Recently, updated in each significantly, with you are balance exciting creating on equivalents along cash research resources of the balance potential and cash. with keep will cash, million, $XXX our December, are our for existing of further We to from raised pro progress shareholders. gives on marketable being our its financial approximately support million. the multiple value forma million our transaction, milestones our of advance for us cash clinical programs a
cell own This update T T results the potent engagers key clinical platform is me cells, programs. power our kill aspects Harpoon’s T technology. of markers. development review of proteins patient's TriTAC novel that, target killer after of in potent most are specific will surface target some a system. to the and cells approach that cells engineered proteins cell factors. a activation our natural T to immune the cells releasing or to unleashing other let cytokines Now, that cells the TriTAC engage you the physically by And and express connect I technology on proprietary
of but is pipeline on oncology the other product current advantageous of treatment cancer. of that immunologic have our uses candidates features be We could compared to a approaches when indications, possible. be also other number Our would TriTAC focused believe to
very to binding, and Half First, cell functions; address domains molecules human have to our is very therapeutic components utilize binding. a a about and activity, utilize binding modular we would which expected therefore are tumour for derived TriTACs potentially our Extension, domain serum single to possible tumors. that We life transiently in and albumin. antibody that applications stable, serum are Life ideal perform a one and cell be more another. T window binding, and off To antibodies primary consist target contributing are target little Furthermore, different has with that larger that to for extension, makes human solid They domain by of half flexible, platform inherently binds albumin similar smaller fragments. these XX% design, three three
by to seen conventional manufacturing standard Second, The intravenous our of to delivery TriTACs methods such designed therapies the completely cell techniques. two all size the our of protein personalized based to freely use antibody avoids CAR-T. a features This complexity administered based Utilizing the and are in antibody, and TriTAC cost third or of these tissue unique connect as and globular TriTAC size to kill and TriTAC with solid into one molecules therapeutic tumor convert T be index every globular is of proteins about weeks. we They a are engagers infusion more tumors. as patients hour be engineered own are cells liquid a tumors to cell that and to relatively our optimize one week T TriTACs typical and to smaller cells or small success compared antibodies. tumors. can allows of And and in bring the of patient's manufactured chose shape finally, diffuse believe them can
where are clinical programs. me we development let with Now, four our review
with version dose a nanogram per kilogram, a Three seven have confirmed dose product serum cancer, RECIST Our castration HPNXXX PSAXX. in and highest metastatic that continuous PSA data including prostate Phase resistant trial. XX% one in XXX patients had reductions, we one enrolled had of of based fixed tested TriTAC patients on lead this reduction of XXXX X/Xa specific targets cohort or membrane achieved update, response candidate treatment and criteria. December the clinical At prostate been partial for or a the X.X enrolled antigen patient for escalation reported PSMA, our
by population this patient to we these encouraged difficult early results. are For treat
into dose advanced We enroll are the to continuing escalation. patients
half able to trial present step are XXX doses We're fixed also planning per dose traditional are for faster patients higher allow. meeting escalation kilogram. where this of dosing medical likely receiving a at much We employ of data allows to in the most to a nanograms would first dose at a a This this in year, than trial this from ASCO. later advancement
is in the of States. with keep advanced prostate the States leading XX% to each reference mind prostate in death cancer is new point the XX,XXX As metastatic Market There patients prostate approximately XX% in Research deaths in present cases third cancer cause shows year. United PSMA a are XXX,XXX to cancer. United cancer and that of
refractory we cells ovarian and enrollment trial. cancer to pancreatic include HPNXXX and clinic, and targets cell non-small second ovarian among TriTAC carcinomas, candidate lung on pancreatic malignant expanded Initially, and is Our breast product cancer, cancer mesothelin. mesothelioma, others. studying this to in patients the in expressed cancer enter began mesothelioma of platinum Mesothelin HPNXXX patients metastatic
we been have has enter XXXX, the nanogram nanograms to beneficial of engager focus some development. advanced is receiving cell dosing step proceeding clinical step and cohorts kilogram from our reported nanograms up in has clinical to Since kilogram across HPNXXX we HPNXXX nine T the in dose cohort per targeted mesothelin mesothelin trial. CAR-T December infusions the conduct X update While XXXX kilogram. first of at efforts, with of XX in weekly The to expectations. is the to our dose Patients XXX trial the At cohort. dosing patients line experience and fixed our per XXX update we have XXX per a been gained one HPNXXX
as from cohort ESMO half to Tsitsi at expect or XXXX, as interim as year trial XXXX. We dose a of ongoing the of provide of expansion end possibly second escalation portion dose initiation data by the [ph], in the well the
the AbbVie, possibly tumors. a and We are cell April a DLLX, XXXX This protocol. progress HPNXXX cohort of the In fixed trial. candidate expect patient IND a in drug dose targets the the XXXX relapsed within initiate by is increase more six months trial. the part the dosing milestone it single DLLX our of clinical in is expected for of first and targets pleased half product quarter second or ASH antigen, the or than in of is multiple of $XX orphan reflecting X/X the XXXX, expressed covered January Phase a fold FDA. TriTAC of myeloma XXX cancers, fourth maturation Our trial of TriTAC HPNXXX to option X HPNXXX the highly submitted the we cohorts December, by initiated X of dosing Phase third the in with indicated and interim with clinical includes majority agreement we to and HPNXXX X/X of in as XXXX. an BCMA. protein B-cell trial refractory ligand And triggered lung product a in third step payment million, other candidate clinical and in received collaboration delta-like initiated which small dose treatment presentation of in a expansion dose program at in which expressing from A update, a micrograms patient We had received June we XXXX. eight and treated our XXXX, designation first data XXX December we
programs four of this of impressive programs past Despite challenges the We the we year, expect half to and second advancement clinical candidate dose the in for was from Harpoon. pipeline data the With XXXX. providing all period trial beyond. the data in portion it product present of in of from interim escalation to a clinic, forward look of our XXXX
for own have cell a reprogram T that to cells We malignancies. immune treat variety engagers a of-the-shelf of patient's a platform wide unique
is turn the pipeline With our positioned and for well drive the shareholder call unique results discussion for over generate that now quarter Our full financial a year exciting of value. will and the Georgia to I fourth data to XXXX.
